Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

被引：0
|
作者：
Awan, Farrukh T. [1 ,2 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Internal Med, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Lymphoid Malignancies Program, Dallas, TX 75390 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [1] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 16 - 17
  • [2] The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
    Schieber, Michael
    Ma, Shuo
    [J]. BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 9 - 17
  • [3] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    [J]. BLOOD, 2021, 137 (08) : 1117 - 1120
  • [4] Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Shadman, Mazyar
    Karve, Sudeep
    Patel, Sima
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Srivastava, Bhavini P.
    Stephens, Deborah M.
    [J]. BLOOD, 2023, 142
  • [5] Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review
    Sugianto, Jeremy Octavian
    Purushotama, Nyoman Bagus Satcitta Ananda
    Ontowirjo, Yudi Ali Putra
    Sutanto, Mario
    Kurniawan, Andree
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1447 - S1447
  • [6] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2019, 134
  • [7] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2019, 134
  • [8] Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Meta-Analysis of Randomized Controlled Trials
    Zhang, Shijia
    Sanchez, Larysa
    Liu, Jieqi
    Chang, Victor
    Goldberg, Stuart L.
    [J]. BLOOD, 2016, 128 (22)
  • [9] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [10] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    [J]. FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
12345